Drugs / T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05350163 | Apr 2022 → Sep 2023 | acute lymphoblastic leukemia, myeloid neoplasm, plasma cell neoplasm | Guenther Koehne | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell Receptor α/β Depleted Donor Lymphocyte Infusions | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05350163 ↗ |
| Modality | Cell therapy | “investigational cellular product of immune cells” NCT05350163 ↗ |